TABLE 2.
Laboratory findings and additional therapeutic data of dogs receiving protocol 1 and protocol 2
| Protocol 1 (n = 13) | Protocol 2 (n = 33) | |
|---|---|---|
| Dogs with alveolar lesions on thoracic radiographs | 8/13 (61%) | 18/33 (54%) |
| Dogs with positive culture | 7/13 (54%) | 16/33 (48%) |
| Range of Ct (qPCR for Bb) | (19‐27.4) | (18‐25.9) |
| Median Ct (qPCR for Bb) | 20 | 21 |
| Dogs with co‐infection with other bacteria | 2/13 (15%) | 3/33 (9%) |
| Dogs with coinfection with M. cynos | 7/12 (58%) | 11/19 (57%) |
| Dogs with TCC of BALF >1000 cells/μL | 7/13 (53%) | 19/28 (67%) |
| Median TCC (range) | 3280 (550‐39 000) | 1700 (560‐52 900) |
| Dogs with % neutrophils on BALF >50% | 9/13 (69%) | 17/28 (60%) |
| Median % neutrophils (range) | 83% (15‐90) | 84% (30‐90) |
| Dogs with concomitant oral antimicrobial treatment | 9/13 (69%) | 13/33 (40%) |
| Use of transport cage for nebulization | 7/13 (54%) | 22/33 (67%) |
Note: Protocol 1: fixed dose of 4 mg/kg of gentamicin with dilution in saline; Protocol 2: fixed undiluted concentration of 5% of gentamicin solution.
Abbreviations: BALF: bronchoalveolar lavage fluid; Bb: Bordetella bronchiseptica; M. cynos: Mycoplasma cynos; qPCR, quantitative polymerase chain reaction; TCC, total cell count of bronchoalveolar lavage.